- Home
- VRDN vs HAPN Comparison
VRDN vs HAPN Comparison
Compare VRDN & HAPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$22.70
Company Overview
Basic Information| Metric | VRDN | HAPN |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2014 | 2008 |
Fundamental Metrics
Financial Performance| Metric | VRDN | HAPN |
|---|---|---|
| Price | $22.70 | $16.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $35.46 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 958.7K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.78 |
| EPS | N/A | ★ 0.94 |
| Revenue | $5,706,000.00 | ★ $314,702,000.00 |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $279.00 | N/A |
| P/E Ratio | ★ N/A | $18.61 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.18 | $16.66 |
| 52 Week High | $34.29 | $21.25 |
Technical Indicators
Market Signals| Indicator | VRDN | HAPN |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 34.75 |
| Support Level | $21.62 | $16.66 |
| Resistance Level | $24.86 | $17.88 |
| Average True Range (ATR) | 0.74 | 0.52 |
| MACD | -0.27 | -0.08 |
| Stochastic Oscillator | 27.13 | 9.92 |
Price Performance
Historical Comparison VRDN
HAPN
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.